3
|
Couturier O, Rousseau C, Pierga JY, Berriolo-Riedinger A, Alberini JL, Girault S, Fumoleau P, Brain E, Abadie-Lacourtoisie S, Vera P, Liehn JC, Olivier P, Uwer L, Cachin F, Sagan C, Bouchet F, Lebas N, Mesleard C, Fourme E, Martin AL, Lovinfosse P, Lacœuille F, Campone M. Abstract P4-01-05: 3’-deoxy-3’-[18F]fluoro-thymidine (18F-FLT) positron emission tomography (PET): An accurate and effective tool for assessing tumor response in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-01-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives : A French multicenter study was promoted by the national French cancer federation (Unicancer R&D) to assess the potential of [18F]FLT (positron emission tomography (PET) biomarker of proliferation)to manage breast cancer neoadjuvant chemotherapy (NAC). The main objective was to compare changes in tumor [18F]FLT uptake to histopathological changes induced by NAC, assuming an arrest of tumor growth related to the effectiveness of NAC.
Methods : 97 patients (age 48.6 +/- 10.2 y.) were included in 13 nuclear medicine centers. All patients were eligible to anthracycline-based NAC for a de novo unifocal breast cancer (ductal n = 84, lobular = 11, other type = 2; stage II n = 75, stage III n = 21 et stage IV n = 1). 90 patients underwent a baseline PET before the onset of NAC (PET1) and a final PET after the end of NAC and before surgery (PET3). PET acquisitions were performed 60±7min after FLT injection. SUVmax (maximum standardized uptake value), SUVpeak (1 cm3 ROI including pixel max) and SUV41 (isocontour 41% of pixel max) were computed. Changes in SUV on PET3 vs PET1 were analyzed in relation to histopathological findings at the end of NAC (Sataloff criteria).
Results : Tumor FLT uptake decreased markedly between TEP1 and TEP3 (SUVmax = 6.2±4.8 vs 1.3±1.2 respectively; SUVpeak = 4.6±3.2 vs 0.9±0.9; SUV41 = 3.6±2.8 vs 0.8±0.7). Total or near-total therapeutic effect (grade A) were obtained in 20 patients, more than 50% therapeutic effect but less than total or near-total effect (grade B) in 37 patients, less than 50% therapeutic effect but visible effect (grade C) in 22 patients, or no therapeutic effect (grade D) in 11 patients. SUVmax decreased dramatically (87.5%) to background levels in all patients with a complete response (grade A). Overall, changes in SUV differed depending on the type of histological response (p<0.01) i.e. SUVmax changes were more pronounced as pathological responses were good: 61% for grade D; 65.7% grade C and 69.8% grade B. The same results were obtained with the two other SUV types.
Conclusions : Pathologic response to NAC in breast cancer can be assessed accurately by FLT.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-05.
Collapse
Affiliation(s)
- O Couturier
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Rousseau
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-Y Pierga
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - A Berriolo-Riedinger
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-L Alberini
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - S Girault
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Fumoleau
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - E Brain
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - S Abadie-Lacourtoisie
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Vera
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-C Liehn
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Olivier
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - L Uwer
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Cachin
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Sagan
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Bouchet
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - N Lebas
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Mesleard
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - E Fourme
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - A-L Martin
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Lovinfosse
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Lacœuille
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - M Campone
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| |
Collapse
|